New 52 Week Low Today

Acumen Pharmaceuticals Inc ABOS:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
14.90quote price arrow up+0.40 (+2.76%)
Volume
291,532
52 week range
13.95 - 26.98

...

Loading . . .
  • Open14.61
  • Day High15.76
  • Day Low13.95
  • Prev Close14.50
  • 52 Week High26.98
  • 52 Week High Date07/01/21
  • 52 Week Low13.95
  • 52 Week Low Date07/28/21

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open14.61
  • Day High15.76
  • Day Low13.95
  • Prev Close14.50
  • 52 Week High26.98
  • 52 Week High Date07/01/21
  • 52 Week Low13.95
  • 52 Week Low Date07/28/21
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.13M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Acumen Pharmaceuticals Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The Company's ACU193 is a humanized monoclonal antibody that selectively targets anti-amyloid-beta oligomer (AbOs), has demonstrated...
Daniel O'Connell
President
Russell Barton
Chief Operating Officer
W. Matthew Zuga
Chief Financial Officer
Address
4435 NORTH FIRST STREET, SUITE 360
Livermore, CA
94551
United States